Pharmaceutical Drug Development Sector Scorecard 2022: High-Value Deals Continue to Drive the Immuno-oncology and Genomics Markets But Several Companies Sell Biosimilar Portfolios - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Pharmaceutical Drug Development Sector Scorecard - Q1 2022 Update - Thematic Research" report has been added to ResearchAndMarkets.com's offering.

Like Q4 2021, the deal landscapes for both immuno-oncology and genomics markets were highly active with several high-value strategic partnerships and acquisitions announced. In immuno-oncology, this includes a $3 billion partnership between Bristol Myers Squibb (BMS) and Century Therapeutics and a $1.2 billion acquisition of Amunix Pharma by Sanofi. In genomics, this includes a $2 billion collaboration between Takeda and Code Biotherapeutics, a $1.6 billion agreement between Novartis and Voyager Therapeutics, and the $1.5 billion acquisition of Gyroscope Therapeutics by Novartis. Another area that saw considerable activity in Q1 2022 was biosimilars, with both Viatris and Biogen exiting this space. There has been no update on Novartis's decision to spin-off its generic arm Sandoz, and the fate of the company remains unknown.

Pharma Continued to Forge Strategic Partnerships with Artificial Intelligence Vendors Throughout Q1 2022.

Many companies included in the Drug Development scorecard have continued to announce partnerships in the artificial intelligence (AI) space since December 2021. Pfizer announced three partnerships in drug discovery, disease severity scoring, and digital therapeutics. Sanofi announced a huge $5.3 billion collaboration with Exscientia in drug discovery, while Thermo Fisher Scientific announced it was partnering with Medidata Acorn AI to optimize clinical trials. Charles River Laboratories and Valo Health are partnering on AI-enabled drug discovery solutions, and Merck KGaA is collaborating with Unlearn.AI to accelerate late-stage trials using AI-based digital twins.

Report Scope

• The Drug Development Scorecard provides a top-down, comprehensive outlook for the key players in the drug development sector over the next two to four years, based on 10 of the major themes set to transform the landscape
• These 10 themes are Immuno-oncology, Regenerative Medicine, Precision & Personalized Medicine, Rare Disease, Biosimilars, Genomics, Microbiome, Nanotechnology, Strategic Alliances, and Artificial Intelligence,
• The scorecard includes 53 companies from across the industry, including biopharmaceutical companies, biosimilar and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs)
• It is important to note that this scorecard is not an assessment of current performance of a company in a theme, but a view of future performance based on current levels of activity and investment
• The methodology section contains information on what data sources were used to generate the thematic scores for each company
• The scorecard is live on the PIC and will be updated quarterly

Key Topics Covered:

• Pharma Theme Map
• Drug Development Scorecard: Key Q1 2022 Updates
• Company Screen
• Thematic Screen
• Valuation Screen

For more information about this report visit https://www.researchandmarkets.com/r/5yw6bk

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.